Drug Trial Radar · NCT06933914
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Last checked: Nov 20, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 30, 2024
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Wuhan Createrna Science and Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
MY008211A tabletsDrug
Participants will receive MY008211A at a dose of 400 mg orally b.i.d
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with adverse events, safety laboratory parameters, vital signs, ECG.Time frame: About 100 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences)
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.